Local
CaniCatiCare Brings 24-Hour Canine Cancer Mutation Test to U.S. Veterinary Clinics
Meet in Common connects news with real conversations. Use ThinkMatch to arrange a Roundtable and meet people to discuss this story.
Roundtables are designed for groups of four, with a shared subject and room for everyone to speak. Come for discussion, with no dating expectation.
Source: Oconomowoc Enterprise

DAEGU, South Korea - November 14, 2026 - CaniCatiCare, a South Korean veterinary precision oncology company, is bringing CaniCancer, its PCR-based tumor mutation test for dogs, to the U.S. market. Unveiled at TechCrunch Disrupt 2026, CaniCancer delivers actionable genetic results within 24 hours of sample receipt. That speed helps veterinarians make targeted treatment decisions sooner.Cancer is one of the leading causes of death in adult dogs. Yet genetic testing in veterinary oncology still relies mostly on next-generation sequencing (NGS), which typically takes two to four weeks. With aggressive cancers like osteosarcoma, that delay can mean missing the best window for treatment.Demand for pet cancer care is growing fast. According to the Veterinary Cancer Society and other sources, about one in four dogs will develop a tumor in its lifetime. Industry estimates project the global veterinary oncology market will grow from $1.82 billion in 2025 to $5.09 billion by 2034.
This excerpt comes from the named source. Read the original for the full reporting.
Read the original at Oconomowoc Enterprise


